WallStSmart

Accelerate Diagnostics Inc (AXDX)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 53785% more annual revenue ($6.30B vs $11.70M). EW leads profitability with a 17.4% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 61/100 (C+).

AXDX

Avoid

25

out of 100

Grade: F

Growth: 2.7Profit: 3.0Value: 5.0Quality: 5.0

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 6.0Quality: 8.5
Piotroski: 3/9Altman Z: 4.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AXDX.

EWUndervalued (+68.7%)

Margin of Safety

+68.7%

Fair Value

$253.29

Current Price

$85.96

$167.33 discount

UndervaluedFair: $253.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AXDX0 strengths · Avg: 0/10

No standout strengths identified

EW4 strengths · Avg: 9.5/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

Areas to Watch

AXDX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$859,9203/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.054/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
46.0x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : AXDX

AXDX has a balanced fundamental profile.

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bear Case : AXDX

The primary concerns for AXDX are EPS Growth, Market Cap, Return on Equity.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.

Key Dynamics to Monitor

AXDX profiles as a value stock while EW is a growth play — different risk/reward profiles.

EW carries more volatility with a beta of 0.87 — expect wider price swings.

EW is growing revenue faster at 16.7% — sustainability is the question.

AXDX generates stronger free cash flow (-5M), providing more financial flexibility.

Bottom Line

EW scores higher overall (61/100 vs 25/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Accelerate Diagnostics Inc

HEALTHCARE · MEDICAL DEVICES · USA

Accelerate Diagnostics, Inc., an in vitro diagnostic company, offers solutions for diagnosing serious infections in the United States, Europe, and the Middle East. The company is headquartered in Tucson, Arizona.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?